Class II
Terminated
Adenosine Injection, USP, 60mg/20mL (3 mg/mL), 20 mL single-dose vial, Rx only, Manufactured by: Teva Pharmaceuticals USA Inc. Parsippany, NJ 07054, NDC 0703-8776-01
Why: Lack of Assurance of Sterility
- Company
- Teva Pharmaceuticals USA
Parsippany, NJ, United States - Reported
- Aug 25, 2021
- Recall started
- Jul 29, 2021
- Ended
- Jun 4, 2024
- Where sold
- Product was distributed Nationwide, including Puerto Rico.
- Amount
- 4,249 vials
- Full product description
- Adenosine Injection, USP, 60mg/20mL (3 mg/mL), 20 mL single-dose vial, Rx only, Manufactured by: Teva Pharmaceuticals USA Inc. Parsippany, NJ 07054, NDC 0703-8776-01
- Lots / codes affected
- Lot #: 100022400, exp. date 04/2023
Class I: could cause serious harm or death. Class II: could cause temporary or treatable problems. Class III: unlikely to cause harm.